Michael Richardson, MD
Family Medicine · Union, MONPI 1477589422
Payments from drug & device makers
Across 247 payments — averaging $15.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$391
- Johnson & Johnson$302
- AstraZeneca$251
- GSK$196
- Amgen$175
- plus $2K from 30 others
What the payments were for
- Food & beverage$3,939100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 62 | $1,050 |
| Novo Nordisk | 25 | $391 |
| Johnson & Johnson(2 entities) | 22 | $302 |
| AstraZeneca | 15 | $251 |
| GSK | 14 | $196 |
| Amgen | 11 | $175 |
| Otsuka America Pharmaceutical, Inc. | 9 | $168 |
| Merck | 10 | $148 |
| Boehringer Ingelheim | 10 | $144 |
| Lilly USA, LLC | 6 | $135 |
| Pfizer | 6 | $99 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $89 |
| Exact Sciences | 4 | $79 |
| Novartis | 5 | $75 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $74 |
| Eisai Inc. | 4 | $72 |
| Abbott | 4 | $63 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Lundbeck LLC | 2 | $35 |
| Tris Pharma Inc | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $30 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Axsome Therapeutics, Inc. | 2 | $28 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Amarin Pharma, Inc. | 2 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Antares Pharma, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Astellas Pharma US Inc | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$3,946 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 68 | $99,568 |
| EliquisApixaban | 81 | $76,837 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 51 | $50,030 |
| XareltoRivaroxaban | 26 | $40,703 |
| MounjaroTirzepatide | 26 | $38,821 |
| JardianceEmpagliflozin | 26 | $23,948 |
| TrulicityDulaglutide | 13 | $21,534 |
| Repatha SureclickEvolocumab | 20 | $15,327 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $11,278 |
| MyrbetriqMirabegron | 16 | $11,075 |
| FarxigaDapagliflozin Propanediol | 13 | $9,346 |
| Aripiprazole | 55 | $7,510 |
| SymbicortBudesonide/Formoterol Fumarate | 23 | $7,338 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $6,052 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $5,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $391 | $99,56868 claims |
| PfizerEliquis | $99 | $76,83781 claims |
| Lilly USA, LLCMounjaro, Trulicity | $135 | $60,35539 claims |
| GSKTrelegy Ellipta, Arexvy | $196 | $55,44475 claims |
| Johnson & JohnsonXarelto | $302 | $40,70326 claims |
| Boehringer IngelheimJardiance | $144 | $23,94826 claims |
| AstraZenecaFarxiga, Symbicort | $251 | $16,68436 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $11,07516 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $89 | $4,69012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Union
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.